Abstract
Rationale: Short bowel syndrome (SBS) is a debilitating condition where parenteral support often is a prerequisite for patients’ survival. Additional medical therapies with acute and prolonged action are wanted to improve quality of life for patients with SBS. Endogenous glucagon-like-peptide 2 (GLP-2) and synthetic GLP-2 analogues possess remarkable intestinotrophic effects. Teduglutide (Takeda) is a marketed short-acting GLP-2 analogue for SBS patients, requiring daily dosing in man. Glepaglutide (Zealand Pharma) is a novel long-acting GLP-2 analogues currently in phase 3 clinical trial for SBS. The aim of the present study was to investigate the acute intestinotrophic effects of short vs long-acting GLP-2 analogues in rats.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
